<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771627</url>
  </required_header>
  <id_info>
    <org_study_id>I 221312</org_study_id>
    <secondary_id>NCI-2012-02755</secondary_id>
    <nct_id>NCT01771627</nct_id>
  </id_info>
  <brief_title>Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers</brief_title>
  <official_title>Pilot Study of Varenicline vs. Nicotine Patch Delivered by a Telephone Quitline to Promote Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies varenicline or nicotine patch in promoting smoking&#xD;
      cessation among current smokers. Varenicline or nicotine patch may help people stop smoking&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if mail delivery of 12 weeks of varenicline results in improved smoking&#xD;
      cessation outcomes relative to nicotine replacement therapy (NRT) in 300 smokers.&#xD;
&#xD;
      II. To determine if delivery of varenicline is cost-effective as compared to nicotine patch.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients undergo general smoking cessation counseling and receive varenicline orally&#xD;
      (PO) twice daily (QD) on days 1-28. Courses repeat every 28 days for up to 12 weeks.&#xD;
&#xD;
      ARM II: Patients undergo general smoking cessation counseling and receive nicotine patch&#xD;
      continuously for 12 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2012</start_date>
  <completion_date type="Actual">August 28, 2015</completion_date>
  <primary_completion_date type="Actual">September 28, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quit Rate</measure>
    <time_frame>4 months</time_frame>
    <description>The quit rate at 4 months will be compared between the 2 groups, using a logistic regression analysis with a 2-side 95% confidence interval.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I (varenicline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (nicotine patch)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (varenicline)</arm_group_label>
    <other_name>Champix</other_name>
    <other_name>Chantix</other_name>
    <other_name>CP-526555</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine patch</intervention_name>
    <arm_group_label>Arm II (nicotine patch)</arm_group_label>
    <other_name>NicoDerm CQ</other_name>
    <other_name>nicotine skin patch</other_name>
    <other_name>nicotine transdermal patch</other_name>
    <other_name>nicotine transdermal system patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cigarette smokers who call the New York State Smokers' Quitline requesting assistance&#xD;
             with quitting smoking&#xD;
&#xD;
          -  State that they are under the care of a primary care physician&#xD;
&#xD;
          -  Are eligible for receipt of pharmacotherapy by mail using the standard NRT criteria&#xD;
&#xD;
          -  Speak English&#xD;
&#xD;
          -  Answer &quot;no&quot; to the following 3 questions:&#xD;
&#xD;
               -  &quot;Have you ever been diagnosed with or treated for a mental health problem like&#xD;
                  major depression, bipolar disorder, dysthymia, or schizoaffective disorder?&quot;&#xD;
&#xD;
               -  &quot;Have you ever had serious thoughts of killing or hurting yourself, ever have any&#xD;
                  intention or plan to carry out these thoughts, or actually attempted to kill&#xD;
                  yourself?&quot;&#xD;
&#xD;
               -  &quot;Is there any reason that you cannot use varenicline/Chantix?&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  State that they are not under the care of a primary care physician&#xD;
&#xD;
          -  Are not eligible for receipt of pharmacotherapy by mail using the standard NRT&#xD;
             criteria&#xD;
&#xD;
          -  Do not speak English&#xD;
&#xD;
          -  Answer &quot;yes&quot; to the question, &quot;have you ever been diagnosed with or treated for a&#xD;
             mental health problem like major depression, bipolar disorder, dysthymia, or&#xD;
             schizoaffective disorder?&quot;&#xD;
&#xD;
          -  Answer &quot;yes&quot; to the question, &quot;have you ever had serious thoughts of killing or&#xD;
             hurting yourself, ever have any intention or plan to carry out these thoughts, or&#xD;
             actually attempted to kill yourself?&quot;&#xD;
&#xD;
          -  Answer &quot;yes&quot; to the question, &quot;is there any reason that you cannot use&#xD;
             varenicline/Chantix?&quot;&#xD;
&#xD;
          -  Are women who are currently pregnant&#xD;
&#xD;
          -  Report that they are unwilling to receive or take varenicline on screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Mahoney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rojewski AM, Hyland A, Mahoney MC. Cooper LM, Zuromski KL, Celestino P, Koutsky J, Toll BA. Feasibility of delivering varenicline through a telephone quitline to promote smoking cessation. J Smoking Cessation 2018</citation>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <results_first_submitted>September 4, 2020</results_first_submitted>
  <results_first_submitted_qc>September 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2020</results_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>available upon request from PI</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>now thru 2021</ipd_time_frame>
    <ipd_access_criteria>available upon request from PI</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Varenicline)</title>
          <description>Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.&#xD;
varenicline: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Nicotine Patch)</title>
          <description>Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.&#xD;
nicotine patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>VAR: mean age 47, 77% white, 10% Hispanic, 46% female NRT: mean age 46, 84% white, 13% Hispanic, 47% female</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Varenicline)</title>
          <description>Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.&#xD;
varenicline: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Nicotine Patch)</title>
          <description>Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.&#xD;
nicotine patch</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="13.9"/>
                    <measurement group_id="B2" value="46.1" spread="13.8"/>
                    <measurement group_id="B3" value="47" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quit Rate</title>
        <description>The quit rate at 4 months will be compared between the 2 groups, using a logistic regression analysis with a 2-side 95% confidence interval.</description>
        <time_frame>4 months</time_frame>
        <population>self reported abstinence</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Varenicline)</title>
            <description>Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.&#xD;
varenicline: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Nicotine Patch)</title>
            <description>Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.&#xD;
nicotine patch</description>
          </group>
        </group_list>
        <measure>
          <title>Quit Rate</title>
          <description>The quit rate at 4 months will be compared between the 2 groups, using a logistic regression analysis with a 2-side 95% confidence interval.</description>
          <population>self reported abstinence</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Varenicline)</title>
          <description>Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.&#xD;
varenicline: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Nicotine Patch)</title>
          <description>Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.&#xD;
nicotine patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ben Toll</name_or_title>
      <organization>MUSC</organization>
      <phone>843-792-9162</phone>
      <email>toll@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

